Eric D Queathem
Overview
Explore the profile of Eric D Queathem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nelson A, Reese L, Rono E, Queathem E, Qiu Y, McCluskey B, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076609
Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to adapt to and exploit their microenvironment for sustained growth. The liver is a common site of metastasis, but the...
2.
Atser M, Wenyonu C, Rowe E, Leung C, Cen H, Queathem E, et al.
J Biol Chem
. 2025 Mar;
:108398.
PMID: 40074083
Pyruvate dehydrogenase kinase (PDK) 1 is one of four isozymes that inhibit the oxidative decarboxylation of pyruvate to acetyl-CoA via pyruvate dehydrogenase. PDK activity is elevated in fasting or starvation...
3.
Queathem E, Moazzami Z, Stagg D, Nelson A, Fulghum K, Hayir A, et al.
Sci Adv
. 2025 Jan;
11(5):eads0535.
PMID: 39879309
Ketogenesis is a dynamic metabolic conduit supporting hepatic fat oxidation particularly when carbohydrates are in short supply. Ketone bodies may be recycled into anabolic substrates, but a physiological role for...
4.
Nelson A, Reese L, Rono E, Queathem E, Qiu Y, McCluskey B, et al.
bioRxiv
. 2024 Dec;
PMID: 39713297
Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to adapt to and exploit their microenvironment for sustained growth. The liver is a common site of metastasis, but the...
5.
Atser M, Wenyonu C, Rowe E, Leung C, Cen H, Queathem E, et al.
bioRxiv
. 2024 Oct;
PMID: 39464135
Pyruvate dehydrogenase kinase (PDK) 1 is one of four isozymes that inhibit the oxidative decarboxylation of pyruvate to acetyl-CoA via pyruvate dehydrogenase. PDK activity is elevated in fasting or starvation...
6.
Queathem E, Stagg D, Nelson A, Chaves A, Crown S, Fulghum K, et al.
bioRxiv
. 2024 Oct;
PMID: 39464122
The progression of metabolic-dysfunction-associated steatotic liver disease (MASLD) to metabolic-dysfunction-associated steatohepatitis (MASH) involves complex alterations in both liver-autonomous and systemic metabolism that influence the liver's balance of fat accretion and...
7.
Queathem E, Nelson A, Puchalska P
Methods Mol Biol
. 2024 Oct;
2855:117-131.
PMID: 39354304
Acetoacetate (AcAc) and D-beta-hydroxybutyrate (D-βOHB), the two major ketone bodies found in circulation, are linked to multiple physiological and pathophysiological states. Therefore, analytical methodologies surrounding the quantification of total ketone...
8.
Nelson A, Queathem E, Puchalska P
Methods Mol Biol
. 2024 Oct;
2855:67-84.
PMID: 39354301
Untargeted metabolomics is a powerful profiling tool for the discovery of possible biomarkers of disease onset and progression. Analytical pipelines applying liquid chromatography (LC) and mass spectrometry (MS)-based methods are...
9.
Queathem E, Moazzami Z, Stagg D, Nelson A, Fulghum K, Hayir A, et al.
bioRxiv
. 2024 Jul;
PMID: 39026753
Therapeutic interventions targeting hepatic lipid metabolism in metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) remain elusive. Using mass spectrometry-based stable isotope tracing and shotgun lipidomics, we established a...
10.
Nelson A, Queathem E, Puchalska P, Crawford P
Nat Metab
. 2023 Dec;
5(12):2062-2074.
PMID: 38092961
Prospective molecular targets and therapeutic applications for ketone body metabolism have increased exponentially in the past decade. Initially considered to be restricted in scope as liver-derived alternative fuel sources during...